Get a Free Glucometer and Strips in 2025: Top Programs That Save You Money

Introduction : Managing diabetes can be expensive, especially when you’re dealing with test strips, lancets, and glucometers. But here’s the good news: In 2025, several trusted programs and brands are offering free glucometers and strips to eligible individuals. Whether you’re newly diagnosed or have been managing diabetes for a long time, you can still get …

Read more

Taurolidine

Taurolidine: A Powerful Antimicrobial for Catheter-Related Infection Prevention

Introduction : Taurolidine is a broad-spectrum antimicrobial agent that is gaining attention for its role in preventing catheter-associated infections. Approved by the US FDA on November 15, 2023, as part of the combination product Defencath (taurolidine and heparin), this compound has shown promising results in reducing infections associated with central venous catheters (CVCs). Catheter-associated bloodstream …

Read more

Opdivo Yervoy: FDA-Approved Breakthrough for Liver Cancer (2025)

Introduction : On April 11, 2025, the U.S. Food and Drug Administration approved the combination of Opdivo and Yervoy as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. This approval is a major advance in immunotherapy, especially for patients who previously had limited treatment …

Read more

Ekterly: A New Hope for Hereditary Angioedema (HAE) Management

Introduction : Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition characterized by sudden swelling in various parts of the body. Managing acute attacks has long been a challenge, but a new FDA-approved oral treatment is offering hope. Acterly, the first-of-its-kind oral plasma kallikrein inhibitor, is revolutionizing the way patients are treated for …

Read more

Blujepa: FDA-Approved Topoisomerase Inhibitor for Uncomplicated UTIs in Females (2025)

Introduction : Urinary tract infections (UTIs) are the most common bacterial infections in women. With increasing antibiotic resistance, the medical community urgently needs new, more effective agents. In a major breakthrough, the US FDA approved Blujepa in March 2025 for the treatment of uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and …

Read more

Nipocalimab Side Effects: A New Hope for Myasthenia Gravis Patients in 2025

Generic Name : Nipocalimab Brand Name : Imaavy Drug Class : Anti-neonatal Fc receptor (FcRn) monoclonal antibody Dosage form : Injection . Introduction : Autoimmune diseases have long presented challenges in treatment and management. One such condition is myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder that causes weakness in skeletal muscles. In 2024, a …

Read more

vanrafia

Vanrafia: A Promising Therapy for Proteinuria Management in Kidney Disorders

Brand Name : Vanrafia Generic Name : atrasentan Drug Class : endothelial antagonist Dosage Form : Oral tablets . Introduction : Having too much protein in your urine isn’t just a symptom—it’s a red flag that indicates kidney damage. If left unchecked, proteinuria can lead to chronic kidney disease (CKD) and even end-stage renal failure. …

Read more

Fitusiran Approval(Qfitlia): March 2025 Marks a New Era in Hemophilia Treatment

Brand name: QfitliaGeneric name: fitusiranDosage form: InjectionDrug class : Antithrombin-targeting siRNA Introduction : In March 2025, a historic breakthrough was made in the world of rare diseases – the US FDA officially approved Fitusiran approval for the treatment of hemophilia A and B, with and without inhibitors. The approval was long-awaited due to the drug’s revolutionary RNA interference …

Read more

Penpulimab-kcqx: FDA-Approved PD-1 Inhibitor for non-keratinizing  Nasopharyngeal Carcinoma

Name of Drug : Penpulimab-kcqx Drug Category : Antineoplastic agent Form : Injection . Introduction : Nasopharyngeal carcinoma (NPC) is a rare cancer that arises in the nasopharynx, most often seen in the non-keratinizing form linked to the Epstein Barr virus. In April 2025, the FDA approved a promising immunotherapy: penpulimab KCQX, a next-generation PD1 …

Read more